Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BG-C9074 |
| Synonyms | |
| Therapy Description |
BG-C9074 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting VTCN1 (B7-H4) linked to a topoisomerase I inhibitor, which potentially induces apoptosis in VTCN1 (B7-H4)-expressing tumor cells (J Clin Oncol 2025 43: 16_suppl, 3033, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BG-C9074 | BG C9074|BGC9074 | BG-C9074 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting VTCN1 (B7-H4) linked to a topoisomerase I inhibitor, which potentially induces apoptosis in VTCN1 (B7-H4)-expressing tumor cells (J Clin Oncol 2025 43: 16_suppl, 3033, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06233942 | Phase I | BG-C9074 BG-C9074 + Tislelizumab | Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 1 |